Cutaneous melanoma incidence in the US is increasing, with an estimated 96 480 cases in 2019 compared with 47 700 in 2000 (https://seer.cancer.gov). Most cutaneous melanomas are limited to the skin (84%), defined as stage I or II disease by the American Joint Committee on Cancer.1 For all stages combined, 5-year mortality rate is 7.8%, but mortality is more likely when cutaneous melanoma has metastasized to lymph nodes or organs (stage III or IV).1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kovarik CL, Chu EY, Adamson AS. Gene Expression Profile Testing for Thin Melanoma: Evidence to Support Clinical Use Remains Thin. JAMA Dermatol. 2020;156(8):837–838. doi:10.1001/jamadermatol.2020.0894
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: